In the Claims

The following amendments are made with respect to the claims in the International application PCT/EP2004/011302.

This listing of claims will replace all prior versions and listings of claims in this application.

1 (currently amended). ~~Use of~~ A method for treating a solid tumour that expresses at least one cellular marker selected from the group comprising CDw52, Claudin 7, Ephrin A1, AMFR, MME, and FGFR3, wherein said method comprises administering to the tumour a ligand of ~~a cellular marker selected from the group comprising CDw52, Claudin 7, Ephrin A1, AMFR, MME, FGFR3 for the preparation of a medicament for the treatment of solid tumours expressing at least~~ one of said ~~cellular~~ markers.

2 (currently amended). [[Use]] The method according to claim 1, wherein the cellular marker expressing solid ~~tumours are selected from the group of bone tumours, in particular slowly proliferating bone tumours~~ tumour is a bone tumour.

3 (currently amended). [[Use]] The method according to claim 1[[or 2]], wherein the cellular marker expressing solid ~~tumours are~~ tumour is selected from the group consisting of giant cell tumours, chondrosarcomas, and osteosarcomas.

4 (currently amended). ~~Use according to any of claims 1 to 3~~The method according to claim 1, wherein the ligand is ~~selected from~~ a cellular marker-specific antibody, a fragment thereof, a cellular marker-binding peptide, [[and]] or a cellular marker-interacting substance.

5 (currently amended). [[Use]] The method according to claim [[4]]1, wherein the ligand is alemtuzumab (Campath-1H).

6 (currently amended). ~~Use according to any of claims 1 to 5~~ The method according to claim 1, wherein the ligand is administered systemically ~~and/or administered~~ or locally, or both.

7 (currently amended). ~~Use according to any of claims 1 to 6~~ The method according to claim 1, wherein the ligand is administered in a pharmaceutical composition to a patient and the ligand is present in the ~~medicament in concentrations~~ composition at a concentration that ~~provide~~ provides an in vivo ~~concentrations~~ concentration of said ligand in [[a]]the patient ~~to be treated~~ of between 0.01 mg/kg/day and 1 mg/kg/day.

8 (currently amended). ~~Use according to any of claims 1 to 7~~ The method according to claim 1, wherein the ligand is ~~for administration~~ administered in combination with at least one other chemotherapeutically active ~~substances~~ substance.

9 (currently amended). ~~Use according to any of claims 1 to 8~~ The method according to claim 1, wherein the ligand is for a specific treatment of mGCs, macrophage-like cells, and fibroblast-like cells of the tumour.

10 (currently amended). [[Use of]] A method for diagnosing a solid tumour wherein said method utilizes a cellular marker selected from the group ~~comprising~~ consisting of CDw52, Claudin 7, Ephrin A1, AMFR, MME, and FGFR3 ~~for the diagnosis of solid tumours expressing at least one of said cellular markers~~.

11 (currently amended). [[Use]] The method according to claim 11, wherein the cellular marker expressing solid tumours ~~are selected from the group of bone tumours~~ is a bone tumour~~, in particular slowly proliferating bone tumours~~.

12 (currently amended). [[Use]] The method according to claim 10[[or 11]], wherein the cellular marker expressing solid ~~tumours are~~ tumour is selected from the group consisting of giant cell tumours, chondrosarcomas, and osteosarcomas.

13 (currently amended). ~~Use according to any of claims 10 to 12~~ The method according to claim 10, wherein the diagnosis comprises ~~the distinction~~ distinguishing between mGCs, macrophage-like cells, and fibroblast-like cells of the tumour.

14 (currently amended). An improved method for screening for ligands of a cellular marker selected from the group ~~comprising~~ consisting of CDw52, Claudin 7, Ephrin A1, AMFR, MME, and FGFR3, ~~comprising~~ wherein said method comprises the steps of:

a) incubating a cell expressing at least one marker selected from CDw52, Claudin 7, Ephrin A1, AMFR, MME, and FGFR3 with a putative ligand,

b) measuring[[,]] if a binding between at least one marker selected from CDw52, Claudin 7, Ephrin A1, AMFR, MME, and FGFR3 and said putative ligand occurs, and

c) in the case of a binding of said ligand to at least one marker is measured, measuring[[,]] if said binding between said at least one marker and said identified ligand also leads to a marker-mediated death of a marker-expressing solid tumour cell.

15 (currently amended). ~~Method~~ A method for the production of a pharmaceutical formulation, comprising the steps of:

~~a) performing a method according to claim 14, and~~

a) incubating a cell expressing at least one marker selected from CDw52, Claudin 7, Ephrin A1, AMFR, MME, and FGFR3 with a putative ligand,

b) measuring if a binding between at least one marker selected from CDw52, Claudin 7, Ephrin A1, AMFR, MME, and FGFR3 and said putative ligand occurs,

c) in the case of a binding of said ligand to at least one marker is measured, measuring if said binding between said at least one marker and said identified ligand also leads to a marker-mediated death of a marker-expressing solid tumour cell, and

~~b) formulating the identified ligand for said at least one marker with pharmaceutically acceptable carriers and/or excipients~~

d) formulating a ligand identified in steps a) through c) with at least one pharmaceutically acceptable carrier and/or excipient.